Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

A Phase 1 First in Human (FIH) Study of AMG 701, an Anti-B-Cell Maturation Antigen (BCMA) Half-Life Extended (HLE) BiTE ® (bispecific T-cell engager) Molecule, in Relapsed/Refractory (RR) Multiple Myeloma (MM)

Blood (2020) 136 (Supplement 1): 28–29.

https://doi.org/10.1182/blood-2020-134063

Published: 2020

Journal Articles

Integrative Analysis of the Genomic and Transcriptomic Landscape of Relapsed/Refractory Multiple Myeloma Patients Treated With Venetoclax in Combination With Bortezomib and Dexamethasone: Biomarker Analyses From the Phase 3 BELLINI Study

Michael E. O'Dwyer, MD, Andrew Spencer, MBBS, FRACP, FRCPA, DM, Shaji K. Kumar, MD, Rakesh Popat, Philippe Moreau, MD, Monique Dail, PhD, Muhammad Jalaluddin, PhD, Xiaoqing Yang, PhD, Xin Lu, Zheng Zha, Fengjiao Dunbar, PhD, Deeksha Vishwamitra, PhD, Christine Mantis, PhD, Amal Melhem-Bertrandt, MD, Jeremy A. Ross, Simon J Harrison, MBBS MRCP (UK) PhDFRCPath (UK) FRACP

Blood (2020) 136 (Supplement 1): 40–41.

https://doi.org/10.1182/blood-2020-134710

Published: 2020

Journal Articles

The Asia-Pacific Myeloma and Related Diseases Registry: Preliminary Results of Real-World Treatment Patterns and Clinical Outcomes

Kim Huynh, BBiomedSc (Hons), PhD, Naomi Aoki, MSc, BSc, Kihyun Kim, MD PhD, Wee Joo Chng, MD PhD, Gin Gin Gan, MBBS, MRCP, FRCP, Chang-Ki Min, MD PhD, Je-Jung Lee, MD PhD, Yeow Tee Goh, MBBS, Cameron Wellard, Zoe McQuilten, MBBS, PhD, Elizabeth M. Moore, PhD, Erica M. Wood, MBBS, FRACP, FRCPA, Andrew Spencer, MBBS, FRACP, FRCPA, DM

Blood (2020) 136 (Supplement 1): 30–31.

https://doi.org/10.1182/blood-2020-136896

Published: 2020

Journal Articles

Real-World Treatment Patterns and Clinical Outcomes in Multiple Myeloma in the Asia-Pacific Region: Methodology and Preliminary Results of the Asia-Pacific Myeloma and Related Diseases Registry (APAC MRDR)

Naomi Aoki, MSc, BSc, Elizabeth M. Moore, PhD, Erica M. Wood, MBBS, FRACP, FRCPA, Zoe McQuilten, Cameron Wellard, Andrew Spencer, MBBS, FRACP, FRCPA, DM

Blood (2019) 134 (Supplement_1): 5518.

https://doi.org/10.1182/blood-2019-124256

Published: 2019

Journal Articles

An Update of Australasian Trends in Allogeneic Stem Cell Transplantation for Myelofibrosis in the Molecular Era

Blood (2019) 134 (Supplement_1): 5719.

https://doi.org/10.1182/blood-2019-126547

Published: 2019

Journal Articles

Efficacy and Safety of Daratumumab, Bortezomib, and Dexamethasone (D-Vd) Versus Bortezomib and Dexamethasone (Vd) in First Relapse Patients (pts) with Multiple Myeloma (MM): Four-Year Update of Castor

Katja C. Weisel, MD, Pieter Sonneveld, Maria-Victoria Mateos, Vania T.M. Hungria, MD PhD, Andrew Spencer, MBBS, FRACP, FRCPA, DM, Jane Estell, FRACP, Wolney G Barreto, Paolo Corradini, Chang-Ki Min, MD PhD, Eva Medvedova, MD, Maria Krevvata, PhD, Sonali Trivedi, Xiang Qin, Huiling Pei, PhD, Jon Ukropec, PhD, Rachel Kobos, MD, Ming Qi, MD PhD, Ajay K Nooka, MDMPH

Blood (2019) 134 (Supplement_1): 3192.

https://doi.org/10.1182/blood-2019-123527

Published: 2019

Journal Articles

Real-World (RW) Multiple Myeloma (MM) Patients (Pts) Remain Under-Represented in Clinical Trials Based on Standard Laboratory Parameters and Baseline Characteristics: Analysis of over 3,000 Pts from the Insight MM Global, Prospective, Observational Study

Blood (2019) 134 (Supplement_1): 1887.

https://doi.org/10.1182/blood-2019-125749

Published: 2019

Journal Articles

Closing the Efficacy and Effectiveness Gap: Outcomes in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated with Ixazomib-Lenalidomide-Dexamethasone (IRd) in Routine Clinical Practice Remain Comparable to the Outcomes Reported in the Phase 3 Tourmaline-MM1 Study

Roman Hajek, Prof, MD PhD, Jiri Minarik, MD PhD, Jan Straub, MD, Ludek Pour, MD, Alexandra Jungova, Jesus G. Berdeja, MD, Mario Boccadoro, Lucie Brožová, MSc, Andrew Spencer, MBBS, FRACP, FRCPA, DM, Frits van Rhee, MD PhD, Jorge Vela-Ojeda, MD PhD, Michael A. Thompson, MD PhD FASCO, Rafat Abonour, MD, Ajai Chari, MD, Gordon Cook, MB ChB, PhD FRCP(Glas), FRCPath, Caitlin L. Costello, MD, Faith E. Davies, MD, Vania T.M. Hungria, MD PhD, Hans C. Lee, MD, Xavier Leleu, MD PhD, Noemi Puig, MD PhD, Robert M. Rifkin, MD, Evangelos Terpos, MD PhD, Saad Z. Usmani, MD FACP, Katja C. Weisel, MD, Jeffrey A. Zonder, Magda Bařinová, MSc, Matyáš Kuhn, MSc, Jiri Silar, MSc, Lenka Capkova, Kenny Galvez, MD, Jin Lu, MDProf, Tomas Skacel, MD, Jennifer Elliott, Brittany Demers, BS, BA, Dawn Marie Stull, Pharm.D., BCOP, Kaili Ren, PhD, Vladimir Maisnar, MD PhD MBA

Blood (2019) 134 (Supplement_1): 1845.

https://doi.org/10.1182/blood-2019-126606

Published: 2019

Journal Articles

T(11;14) and High BCL2 Expression Are Predictive Biomarkers of Response to Venetoclax in Combination with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Biomarker Analyses from the Phase 3 Bellini Study

Blood (2019) 134 (Supplement_1): 142.

https://doi.org/10.1182/blood-2019-126094

Published: 2019

Journal Articles

Real-World Outcome for Newly Diagnosed Patients with Functional High-Risk Myeloma - a Myeloma and Related Diseases Registry Analysis

Andrew Spencer, MBBS, FRACP, FRCPA, DM, Peter Mollee, MBBS, MMSc, FRACP, FRCPA, Hilary Anne Blacklock, FRACP, Simon Harrison, MBBS, MRCP, FRCPath, FRACP, PhD, Hang Quach, MBBS, FRACP, FRCPA, MD, P. Joy Ho, MBBS DPhil FRACP FRCPA, Ruth Spearing, MD, Jay Hocking, MBBS, FRACP, FRCPA, Bradley Augustson, MBBS FRACP FRCPA, H. Miles Prince, MBBS (Hons), MD FRACP, FRCPA, AFRCMA, MACD, Elizabeth M. Moore, PhD, Zoe McQuilten, Erica M. Wood, MBBS, FRACP, FRCPA, Cameron Wellard

Blood (2019) 134 (Supplement_1): 269.

https://doi.org/10.1182/blood-2019-129431

Published: 2019

Journal Articles

Metabolomic Profiling of Serum from Myeloma and MGUS Patients - a Novel Strategy to Identify Potential Biomarkers of Myeloma Development and Progression

Samar Masoumi Moghaddam, MD PhD, Dovile Anderson, PhD, Darren Creek, PhD, Tiffany Khong, BSc, PhD, Andrew Spencer, MBBS, FRACP, FRCPA, DM

Blood (2018) 132 (Supplement 1): 1891.

https://doi.org/10.1182/blood-2018-99-117541

Published: 2018

Journal Articles

Resistance to Nutrient Deprivation Via Metabolic Re-Programming As Mechanism of 'Metastasis' Promotion in Multiple Myeloma

Ioanna Savvidou, MD, Sahan Chandrasekara, MD, Maoshan Chenn, PhD, Tiffany Khong, BSc, PhD, Andrew Spencer, MBBS, FRACP, FRCPA, DM

Blood (2018) 132 (Supplement 1): 3218.

https://doi.org/10.1182/blood-2018-99-112802

Published: 2018

Journal Articles

Maintenance Therapy with the Oral Proteasome Inhibitor (PI) Ixazomib Significantly Prolongs Progression-Free Survival (PFS) Following Autologous Stem Cell Transplantation (ASCT) in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Phase 3 Tourmaline-MM3 Trial

Blood (2018) 132 (Supplement 1): 301.

https://doi.org/10.1182/blood-2018-99-112079

Published: 2018

Journal Articles

Updated Results from the Phase 2 Centaurus Study of Daratumumab (DARA) Monotherapy in Patients with Intermediate-Risk or High-Risk Smoldering Multiple Myeloma (SMM)

Blood (2018) 132 (Supplement 1): 1994.

https://doi.org/10.1182/blood-2018-99-113467

Published: 2018

Journal Articles

Transplant Status Does Not Impact the Selection of Induction Regimens for Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) in the Insight MM Prospective, Observational Study

Blood (2018) 132 (Supplement 1): 3289.

https://doi.org/10.1182/blood-2018-99-112846

Published: 2018

Journal Articles

Efficacy and Safety of Daratumumab, Bortezomib, and Dexamethasone (D-Vd) Versus Bortezomib and Dexamethasone (Vd) in First Relapse Patients: Two-Year Update of Castor

Maria-Victoria Mateos, MD PhD, Pieter Sonneveld, MD PhD, Vania T. M. Hungria, MD PhD, Ajay K Nooka, MD MPH, Jane Estell, FRACP, Wolney G Barreto, Paolo Corradini, MD, Chang-Ki Min, MD PhD, Eva Medvedova, MD, Katja Weisel, MD, Christopher Chiu, PhD, Jordan M. Schecter, Himal Amin, Xiang Qin, Ming Qi, Andrew Spencer, MBBS, FRACP, FRCPA, DM

Blood (2018) 132 (Supplement 1): 3270.

https://doi.org/10.1182/blood-2018-99-112554

Published: 2018

Journal Articles

Evaluation of Sustained Minimal Residual Disease (MRD) Negativity in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated with Daratumumab in Combination with Lenalidomide Plus Dexamethasone (D-Rd) or Bortezomib Plus Dexamethasone (D-Vd): Analysis of Pollux and Castor

Hervé Avet-Loiseau, MD PhD, Jesus F San-Miguel, MD PhD, Tineke Casneuf, PhD, Shinsuke Iida, MD PhD, Sagar Lonial, MD, Saad Z. Usmani, MD, Andrew Spencer, MBBS, FRACP, FRCPA, DM, Philippe Moreau, Torben Plesner, MD DSc, Katja Weisel, MD, Jon Ukropec, PhD, Linda Okonkwo, Sonali Trivedi, Christopher Joseph Velas, BS, Xiang Qin, Ming Qi, MD PhD, Christopher Chiu, PhD, Nizar Bahlis, MD

Blood (2018) 132 (Supplement 1): 3272.

https://doi.org/10.1182/blood-2018-99-113177

Published: 2018

Journal Articles

Early Serum Free Light Chain (SFLC) Kinetics Is Highly Predictive of Renal Response in Carfilzomib/ Dexamethasone (Cfz/Dex) in Myeloma (MM) Patients with Renal Impairment (RI) — Interim Analysis of the Australian ALLG MM16 Trial

Phoebe Joy Ho, MBBS DPhil FRACP FRCPA, Andrew Spencer, MBBS, FRACP, FRCPA, DM, Peter Mollee, FRACP, FRCPA, MBBS, MMSc, Anoop K Enjeti, MBBS, FRCPA, MD MRCP, Noemi Horvath, MBBS FRACP FRCPA, Christian E Bryant, MBBS, PhD FRACP, FRCPA, Judith Trotman, Simon Gibbs, FRACP, FRCPA, MBBS, Douglas E Joshua, BSc(Hons) MBBS DPhil FRACP FRCPA

Blood (2018) 132 (Supplement 1): 3283.

https://doi.org/10.1182/blood-2018-99-110664

Published: 2018

Journal Articles

Preliminary Analysis of the Australasian Leukaemia and Lymphoma Group (ALLG) MM17 Trial: Response Adaptive Salvage Treatment with Carfilzomib-Thalidomide-Dexamethasone (KTd) for Newly Diagnosed Transplant Eligible Multiple Myeloma Patients Failing Front-Line Bortezomib-Based Induction Therapy

Andrew Spencer, MBBS, FRACP, FRCPA, DM, Hang Quach, MD FRACP, FRCPA, MBBS, Noemi Horvath, MBBS FRACP FRCPA, Ian H. Kerridge, FRACP, FRCPA, MPhil, BA, Flora Yuen, BBiomedSc, Edwin Sze-Hung Lee, MD FRACP, FRCP, FRCPA, FRCPath, Edward S. Morris, BMBS, DM, Anna Kalff, MBBS, Krystal Bergin, Shreerang Sirdesai, MBBS, FRACP, FRCPA, Malgorzata Gorniak, BSc, Sridurga Mithraprabhu, PhD MSc, Tiffany Khong, BSc, PhD, John Reynolds, PhD

Blood (2018) 132 (Supplement 1): 3279.

https://doi.org/10.1182/blood-2018-99-113982

Published: 2018

Journal Articles

A New Generation XIAP Inhibitor Induces Apoptosis of Human Myeloma Cells and Synergises with Conventional and Novel Anti-Myeloma Therapeutics.

Tiffany Khong, PhD, BSc(Hons), Andrew Spencer, MBBS, FRACP, FRCPA, DM

Blood (2007) 110 (11): 4787.

https://doi.org/10.1182/blood.V110.11.4787.4787

Published: 2007

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

A Phase 1 First in Human (FIH) Study of AMG 701, an Anti-B-Cell Maturation Antigen (BCMA) Half-Life Extended (HLE) BiTE ® (bispecific T-cell engager) Molecule, in Relapsed/Refractory (RR) Multiple Myeloma (MM)

Integrative Analysis of the Genomic and Transcriptomic Landscape of Relapsed/Refractory Multiple Myeloma Patients Treated With Venetoclax in Combination With Bortezomib and Dexamethasone: Biomarker Analyses From the Phase 3 BELLINI Study

The Asia-Pacific Myeloma and Related Diseases Registry: Preliminary Results of Real-World Treatment Patterns and Clinical Outcomes

Real-World Treatment Patterns and Clinical Outcomes in Multiple Myeloma in the Asia-Pacific Region: Methodology and Preliminary Results of the Asia-Pacific Myeloma and Related Diseases Registry (APAC MRDR)

An Update of Australasian Trends in Allogeneic Stem Cell Transplantation for Myelofibrosis in the Molecular Era

Efficacy and Safety of Daratumumab, Bortezomib, and Dexamethasone (D-Vd) Versus Bortezomib and Dexamethasone (Vd) in First Relapse Patients (pts) with Multiple Myeloma (MM): Four-Year Update of Castor

Real-World (RW) Multiple Myeloma (MM) Patients (Pts) Remain Under-Represented in Clinical Trials Based on Standard Laboratory Parameters and Baseline Characteristics: Analysis of over 3,000 Pts from the Insight MM Global, Prospective, Observational Study

Closing the Efficacy and Effectiveness Gap: Outcomes in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated with Ixazomib-Lenalidomide-Dexamethasone (IRd) in Routine Clinical Practice Remain Comparable to the Outcomes Reported in the Phase 3 Tourmaline-MM1 Study

T(11;14) and High BCL2 Expression Are Predictive Biomarkers of Response to Venetoclax in Combination with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Biomarker Analyses from the Phase 3 Bellini Study

Real-World Outcome for Newly Diagnosed Patients with Functional High-Risk Myeloma - a Myeloma and Related Diseases Registry Analysis

Metabolomic Profiling of Serum from Myeloma and MGUS Patients - a Novel Strategy to Identify Potential Biomarkers of Myeloma Development and Progression

Resistance to Nutrient Deprivation Via Metabolic Re-Programming As Mechanism of 'Metastasis' Promotion in Multiple Myeloma

Maintenance Therapy with the Oral Proteasome Inhibitor (PI) Ixazomib Significantly Prolongs Progression-Free Survival (PFS) Following Autologous Stem Cell Transplantation (ASCT) in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Phase 3 Tourmaline-MM3 Trial

Updated Results from the Phase 2 Centaurus Study of Daratumumab (DARA) Monotherapy in Patients with Intermediate-Risk or High-Risk Smoldering Multiple Myeloma (SMM)

Transplant Status Does Not Impact the Selection of Induction Regimens for Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) in the Insight MM Prospective, Observational Study

Efficacy and Safety of Daratumumab, Bortezomib, and Dexamethasone (D-Vd) Versus Bortezomib and Dexamethasone (Vd) in First Relapse Patients: Two-Year Update of Castor

Evaluation of Sustained Minimal Residual Disease (MRD) Negativity in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated with Daratumumab in Combination with Lenalidomide Plus Dexamethasone (D-Rd) or Bortezomib Plus Dexamethasone (D-Vd): Analysis of Pollux and Castor

Early Serum Free Light Chain (SFLC) Kinetics Is Highly Predictive of Renal Response in Carfilzomib/ Dexamethasone (Cfz/Dex) in Myeloma (MM) Patients with Renal Impairment (RI) — Interim Analysis of the Australian ALLG MM16 Trial

Preliminary Analysis of the Australasian Leukaemia and Lymphoma Group (ALLG) MM17 Trial: Response Adaptive Salvage Treatment with Carfilzomib-Thalidomide-Dexamethasone (KTd) for Newly Diagnosed Transplant Eligible Multiple Myeloma Patients Failing Front-Line Bortezomib-Based Induction Therapy

A New Generation XIAP Inhibitor Induces Apoptosis of Human Myeloma Cells and Synergises with Conventional and Novel Anti-Myeloma Therapeutics.

Email alerts

ASH Publications

American Society of Hematology